Kala recruiting for study of KPI-012 in participants with PCED

According to a post to the ClinicalTrials.gov website first posted on February 14, Kala Pharmaceuticals is recruiting for a Phase 2 study of participants diagnosed with persistent corneal epithelial defect, or PCED, at multiple U.S. centers to assess the safety and efficacy of KPI-012, a topical mesenchymal stem cell secretome therapy. After an initial cohort of at least 2 participants to evaluate the safety of the high strength product, participants in the second cohort will be randomized to treatment with either the product or vehicle for 8 weeks. The percentage of healing will be compared between groups treated with product and vehicle. The total length of study participation will be approximately 34 weeks, according to the post. Reference Link